Cargando…

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Rigosertib has demonstrated therapeutic activity for patients with high-risk myelodysplastic syndrome (MDS) in clinical trials. However, the role of rigosertib in MDS has not been thoroughly characterized. In this study, we found out that rigosertib induced apoptosis, blocked the cell cycle at the G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Feng, He, Qi, Li, Xiao, Chang, Chun-Kang, Wu, Ling-Yun, Zhang, Zheng, Liu, Li, Shi, Wen-Hui, Zhu, Yang, Zhao, You-Shan, Gu, Shu-Cheng, Fei, Cheng-Ming, Guo, Juan, Wu, Dong, Zhou, Liyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255183/ https://www.ncbi.nlm.nih.gov/pubmed/25472472 http://dx.doi.org/10.1038/srep07310

Ejemplares similares

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
por: Hyoda, Tomoko, et al.
Publicado: (2015)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
por: Nazha, Aziz, et al.
Publicado: (2017)

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2017)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Signal transduction inhibitors in treatment of myelodysplastic syndromes
por: Bachegowda, Lohith, et al.
Publicado: (2013)

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2016)

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020)

Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome
por: Park, Hee Sue, et al.
Publicado: (2017)

Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
por: Zhang, Xiaoying, et al.
Publicado: (2023)

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
por: Dietrich, Peter, et al.
Publicado: (2017)

Dysregulation of macrophage development and phenotype in diabetic human macrophages can be rescued by Hoxa3 protein transduction
por: Alrdahe, Salma, et al.
Publicado: (2019)

Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes
por: Xu, Feng, et al.
Publicado: (2015)

The yin-yang of immunity: Immune dysregulation in myelodysplastic syndrome with different risk stratification
por: Peng, Xiaohuan, et al.
Publicado: (2022)

From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review
por: Comont, Thibault, et al.
Publicado: (2021)

Clinical and Molecular Insights in Erythropoiesis Regulation of Signal Transduction Pathways in Myelodysplastic Syndromes and β-Thalassemia
por: Parisi, Sarah, et al.
Publicado: (2021)

Oxidative Stress Parameters Can Predict the Response to Erythropoiesis-Stimulating Agents in Myelodysplastic Syndrome Patients
por: Gonçalves, Ana Cristina, et al.
Publicado: (2021)

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines
por: Prasad, Anil, et al.
Publicado: (2016)

Decitabine of Reduced Dosage in Chinese Patients with Myelodysplastic Syndrome: A Retrospective Analysis
por: Li, Xiao, et al.
Publicado: (2014)

Clinical significance of hyaluronan levels and its pro-osteogenic effect on mesenchymal stromal cells in myelodysplastic syndromes
por: Fei, Cheng-Ming, et al.
Publicado: (2018)

IRTKS Promotes Insulin Signaling Transduction through Inhibiting SHIP2 Phosphatase Activity
por: Wu, Chongchao, et al.
Publicado: (2019)

Resveratrol ameliorates diet-induced dysregulation of lipid metabolism in zebrafish (Danio rerio)
por: Ran, Gai, et al.
Publicado: (2017)

Signal Transduction Inhibitors as Promising Anticancer Agents
por: Kumar, Raj, et al.
Publicado: (2015)

Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS)
por: Xie, Xiaoqing, et al.
Publicado: (2021)

Integration Analysis of JAK2 or RUNX1 Mutation With Bone Marrow Blast Can Improve Risk Stratification in the Patients With Lower Risk Myelodysplastic Syndrome
por: Fang, Ying, et al.
Publicado: (2021)

Amelioration of Radiation-induced Skin Injury by HIV-TAT-Mediated Protein Transduction of RP-1 from Rana pleurade
por: Zhang, Shuyu, et al.
Publicado: (2013)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Sesamin: A Promising Therapeutic Agent for Ameliorating Symptoms of Diabetes
por: Huang, Shu-Ming, et al.
Publicado: (2023)

MicroRNA-122-5p ameliorates tubular injury in diabetic nephropathy via FIH-1/HIF-1α pathway
por: Cheng, Li, et al.
Publicado: (2022)

An Agent-Based Model of Signal Transduction in Bacterial Chemotaxis
por: Miller, Jameson, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vserik3qb9o19bdi816pe8a45l